Basal nitric oxide modulates vascular effects of a peptide activating protease-activated receptor 2

Cardiovascular Research

Volumn 60, Issue 2, 2003, Pages 431-437

  Cicala, Carla ^a   Morello, Silvana ^a   Vellecco, Valentina ^a   Severino, Beatrice ^a   Sorrentino, Ludovico ^a   Cirino, Giuseppe ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

cAMP; cGMP; Nitric oxide; PAR2; Vasorelaxation

Indexed keywords

1H 1,2,4 OXADIAZOLO[4,3 A]QUINOXALIN 1 ONE; 9 (TETRAHYDRO 2 FURYL)ADENINE; ADENYLATE CYCLASE; ADENYLATE CYCLASE INHIBITOR; ENZYME INHIBITOR; GELDANAMYCIN; GUANYLATE CYCLASE INHIBITOR; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; NITROPRUSSIDE SODIUM; PHOSPHODIESTERASE INHIBITOR; PROTEINASE ACTIVATED RECEPTOR 2; ROLIPRAM; SERYLLEUCYLISOLEUCYLGLYCYLARGINYLLEUCINAMIDE; UNCLASSIFIED DRUG; VASODILATOR AGENT;

ANIMAL TISSUE; ARTERY ENDOTHELIUM; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG ANTAGONISM; DRUG MECHANISM; ENDOTHELIUM; ENZYME INHIBITION; IN VITRO STUDY; INCUBATION TIME; INTERMETHOD COMPARISON; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; RAT; REGULATORY MECHANISM; THORACIC AORTA; TISSUE CULTURE; VASODILATATION;

ADENINE; ADENYLATE CYCLASE; ANIMALS; AORTA; CYCLIC AMP; CYCLIC GMP; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIUM, VASCULAR; MALE; NITRIC OXIDE; OLIGOPEPTIDES; PHOSPHODIESTERASE INHIBITORS; RATS; RATS, WISTAR; RECEPTOR, PAR-2; ROLIPRAM; VASODILATOR AGENTS;

EID: 0242627401     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0008-6363(03)00565-0     Document Type: Article

References (30)

1. Dery O., Corvera C.U., Steinhoff M., Bunnett N.W. Proteinase-activated receptors: novel mechanisms of signalling by serine proteases. Am. J. Physiol. 274:1998;C1429-C1452.
2. Nystedt S., Emilsson K., Wahlestedt C., Sundelin J. Molecular cloning of a potential proteinase activated receptor. Proc. Natl. Acad. Sci. U. S. A. 91:1994;9208-9212.
3. Molino M., Barnathan E.S., Numerof R., Clark J., Dreyer M., Cumashi A.et al. Interactions of mast cell tryptase with thrombin receptors and PAR-2. J. Biol. Chem. 272:1997;4043-4049.
4. Fox M.T., Harriott P., Walker B., Stone S.R. Identification of potential activators of proteinase activated receptor-2. FEBS lett. 417:1997;267-269.
5. D'Andrea M.R., Derian C.K., Leturcq D., Baker S.M., Brunmark A., Ling P.et al. Characterization of protease activated receptor-2 immunoreactivity in normal human tissues. J. Histochem. Cytochem. 46:1998;157-164.
6. Nystedt S., Ramakrishnan V., Sundelin J. The proteinase-activated receptor 2 is induced by inflammatory mediators in human endothelial cells. Comparison with the thrombin receptor. J. Biol. Chem. 21:1996;14010-14915.
7. Cicala C., Pinto A., Bucci M., Sorrentino R., Walker B., Harriot P.et al. Protease-activated receptor-2 involvement in hypotension in normal and endotoxemic rats in vivo. Circulation. 99:1999;2590-2597.
8. Hamilton J.R., Frauman A.G., Cocks T.M. Increased expression of protease activated receptor 2 (PAR2) and PAR4 in human coronary artery by inflammatory stimuli unveils endothelium-dependent relaxations to PAR2 and PAR4 agonists. Circ. Res. 89:2001;92-98.
9. Cicala C. Protease activated receptor 2 and the cardiovascular system. Br. J. Pharmacol. 135:2002;14-20.
10. 2, in rat vascular and gastric smooth muscle. Can. J. Physiol. Pharmacol. 73:1995;1203-1207.
11. Hollenberg M.D., Saiffedine M., Al-Ani B. Proteinase activated receptor-2 in rat aorta: structural requirements for agonist activity of receptor-activating peptides. Mol. Pharmacol. 49:1996;229-233.
12. Magazine H.I., King J.M., Srivastava K.D. Protease activated receptors modulate aortic vascular tone. Int. J. Cardiol. 53:1996;S75-S80.
13. Saiffedine M., Al-Ani B., Cheng C.H., Wang L., Hollenberg M.D. Rat proteinase-activated receptor-2 (PAR-2): cDNA sequence and activity of receptor-derived peptides in gastric and vascular tissue. Br. J. Pharmacol. 118:1996;521-530.
14. Emilsson K., Wahlestedt C., Sun M., Nystedt S., Owman C., Sundelin J. Vascular effects of proteinase activated receptor 2 agonist peptide. J. Vasc. Res. 34:1997;267-272.
15. Cheung W., Andrade-Gordon P., Derian C.K., Damiano B.P. Receptor activating peptides distinguish thrombin receptor (PAR1) and protease activated receptor 2 (PAR2) mediated hemodynamic responses in vivo. Can. J. Physiol. Pharmacol. 76:1998;16-25.
16. Cicala C., Morello S., Santagada V., Caliendo G., Sorrentino L., Cirino G. Pharmacological dissection of vascular effects caused by activation of protease-activated receptor 1 and 2 in anesthetized rats. FASEB J. 15:2001;1433-1435.
17. Garthwaite J., Southam E., Boulton C.L., Nielsen E.B., Schmidt K., Mayer B. Potent and selective inhibition of nitric oxide-sensitive guanylyl cyclase by 1H-[1,2,4] oxadiazolo [4,3-a] quinoxalin-1-one (ODQ). Mol. Pharmacol. 48:1995;185-188.
18. Garcia-Gardena G., Fan R., Shah V., Sorrentino R., Cirino G., Papapetropoulos A.et al. Dynamic activation of endothelial nitric oxide synthase by Hsp 90. Nature. 392:1998;821-824.
19. Xu H.L., Feinstein D.L., Santizo R.A., Koenig H.M., Pelligrino D.A. Agonist-specific differences in mechanisms mediating eNOS-dependent pial arteriolar dilation in rats. Am. J. Physiol. Heart Circ. Physiol. 282:2002;H237-H243.
20. Bakker E.N., Sipkema P. Permissive effect of nitric oxide in arachidonic acid induced dilation in isolated rat arterioles. Cardiovasc. Res. 38:1998;782-787.
21. Fiscus R.R., Hao H., Wang X., Arden W.A., Diana J.N. Nitroglycerin (exogenous nitric oxide) substitutes for endothelium-derived nitric oxide in potentiating vasorelaxations and cyclic AMP elevations induced by calcitonin gene-related peptide (CGRP) in rat aorta. Neuropeptides. 26:1994;133-144.
22. Toyoshima H., Nasa Y., Hashizume Y., Koseki Y., Isayama Y., Koshaka Y.et al. Modulation of cAMP-mediated vasorelaxation by endothelial nitric oxide and basal cGMP in vascular smooth muscle. J. Cardiovasc. Pharmacol. 32:1998;543-551.
23. Zellers T.M., Wu Y.Q., Mccormick J., Vanhoutte P.M. Prostacyclin-induced relaxations of small porcine pulmonary arteries are enhanced by the basal release of endothelium-derived nitric oxide through an effect on cyclic GMP-inhibited-cyclic AMP phosphodiesterase. Acta Pharmacol. Sin. 21:2000;131-138.
24. Moffatt J.D., Cocks T.M. Endothelium-dependent and independent responses to protease-activated receptor-2 (PAR-2) activation in mouse isolated renal arteries. Br. J. Pharmacol. 125:1998;591-594.
25. Molino M., Raghunatah P.N., Kuo A., Ahuja M., Hoxie J.A., Brass L.F.et al. Differential expression of functional protease-activated-receptor-2 (PAR-2) in human vascular smooth muscle cells. Arterioscler. Thromb. Vasc. Biol. 18:1998;825-832.
26. Eckly A.E., Lugnier C. Role of phosphodiesterase III and IV in the modulation of vascular cyclic AMP content by the NO/cyclic GMP pathway. Br. J. Pharmacol. 113:1994;445-450.
27. Lugnier C., Schini V.B. Characterization of cyclic nucleotide phosphodiesterases from cultured bovine aortic endothelial cells. Biochem. Pharmacol. 39:1990;75-84.
28. Souness J.E., Diocee B.K., Martin W., Moodie S.A. Pig aortic endothelial-cell cyclic nucleotide phosphodiesterases. Biochem. J. 266:1990;127-132.
29. Gray D.W., Marshall I. Novel signal transduction pathway mediating endothelium-dependent β-adrenoceptor vasorelaxation in rat thoracic aorta. Br. J. Pharmacol. 107:1992;684-690.
30. Zhang X., Hintze T.H. cAMP signal transduction cascade, a novel pathway for the regulation of endothelial nitric oxide production in coronary blood vessels. Arterioscler. Thromb. Vasc. Biol. 21:2001;797-803.